We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Cayman 1-Docosahexaenoyl-2-Hydroxy-Sn-Glycero-3-Pc; 10 Mg; 162440-05-3; ≥90%
Product Description
C16 Ceramide-d7 is intended for use as an internal standard for the quantification of C16 ceramide (d18:1/16:0) by GC- or LC-MS. C16 Ceramide is a sphingolipid. It incorporates into the mitochondrial outer membrane and forms channels that increase its permeability. C16 Ceramide levels are increased by PPMP or MAPP in isolated human neutrophils and are correlated with an increase in apoptosis. It accumulates in the lungs of patients with cystic fibrosis compared with the lungs of patients with pulmonary hypertension. Plasma levels of C16 ceramide are also increased in patients with acute coronary syndrome, and an increased plasma ratio of C16 to C24:0 ceramide is associated with major adverse cardiac events. It is also increased in tumor tissue from patients with breast cancer and is associated with metastatic cancer.
WARNING This product is not for human or veterinary use.
Technical Information
- Cer-d7 (d18:1-d7/16:0)
- Ceramide-d7 (d18:1-d7/16:0)
- N-hexadecanoyl-D-erythro-Sphingosine-d7
- DMF: 0.15 mg/ml
Shipping & Storage Information
| SKU | CAYM-37340-10 |
|---|---|
| Featured | No |
| Supplier Part Number | 37340-10 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| Temperature | -80 |
| Refrigerated-Frozen | Frozen |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 2 |
| Hazardous | Y |
| CAS Number | 162440-05-3 |
| Energy Star | No |
| Green | No |
| ACT Ecolabel | No |
| Controlled | N |